Effects of short-term hormone replacement on serum leptin levels in postmenopausal women

• Published in: Clinical endocrinology (Oxford) Vol. 51; no. 4; pp. 415 - 422
• Main Authors: Lavoie, Helene B., Taylor, Ann E., Sharpless, Julie L., Anderson, Ellen J., Strauss, Carrie C., Hall, Janet E.
• Format: Journal Article
• Language: English
• Published: Oxford BSL Blackwell Science Ltd 01.10.1999; Blackwell; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biological and medical sciences; Body Composition; Body Mass Index; Estradiol - therapeutic use; Estrogen Replacement Therapy; Female; Genital system. Reproduction; Humans; Leptin - blood; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Postmenopause - blood; Progesterone - therapeutic use; United States; North America; America; Human; Replacement therapy; Treatment efficiency; Estrogen; Fat mass; Body composition; Progestagen; Blood plasma; Leptin; Postmenopause; Adult; Female; Progesterone; Elderly; Age; Comparative study
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1046/j.1365-2265.1999.00796.x

OBJECTIVE Leptin is a hormone which is secreted by adipocytes and appears to influence the reproductive axis. Previous studies have demonstrated higher leptin levels in relation to body fat mass in women compared to men, higher levels in normally cycling compared to postmenopausal women, and a decrease in leptin levels with increased age. The purpose of this study was to determine whether oestrogen replacement with or without progesterone increases serum leptin levels in postmenopausal women, independently of changes in body fat, and to determine if ageing affects leptin levels at baseline or in response to hormone replacement. PATIENTS Twenty‐one healthy postmenopausal women on no hormone replacement were studied at baseline, after 1 month of oestrogen (E2: estraderm 50 μg/day) and after a further month of oestrogen and 7 days of progesterone (P: progesterone 100 mg per vagina bid) designed to achieve physiological hormone levels. Subjects included 11 younger (45–55 years) and 10 older (70–80 years) postmenopausal women. RESULTS The relationship between leptin and the absolute fat mass (% body fat × weight [kg]) at baseline was not different between the younger and older postmenopausal women. The adequacy of physiological hormone replacement was confirmed in all subjects. Despite the absence of an effect of hormone replacement on weight, body mass index (BMI), % and absolute fat mass (bioimpedance) or waist‐hip ratio, there was an increase in serum leptin levels with hormone replacement (15.4 ± 1.7, 17.6 ± 1.7, and 18.1 ± 1.6 μg/l; mean ± SEM at baseline, with E2, and with E2 + P, respectively; P < 0.001 vs. baseline) for the group as a whole. An increase in leptin with hormonal treatment was seen in both the younger (15.1 ± 2.1, 18.1 ± 2.4, and 18.5 ± 1.9 μg/l; P < 0.01) and the older (15.7 ± 2.8, 17.0 ± 2.5, 17.7 ± 2.8 μg/l; P = 0.06) postmenopausal women. CONCLUSIONS (1) Short‐term physiological oestrogen replacement increases serum leptin levels in postmenopausal women independently of changes in fat mass; and (2) physiological progesterone replacement does not influence leptin levels in postmenopausal women.